ImmuPharma focused on securing P140 licensing deal in 2026

ImmuPharma PLC (AIM:IMM, FRA:25I), the drug discovery company, says it is in active discussions with potential global commercial partners for its lead autoimmune therapy P140, with management targeting a licensing transaction this year. The update came as the company published final results for the 12 months to 31 December, with chief executive Tim McCarthy describing the period ahead as "pivotal.